Skip to main content
Marie Wislez on Muck Rack

Marie Wislez

As seen in: MDPI, Taylor & Francis Online, Cell Press, The Lancet, European Respiratory Journal, Lung Cancer
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Marie

Contact Marie, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study

|
By David Planchard, Nathalie Cozic, Maria Fernanda Mosele, Noemie Corcos, Loic Le Bescond, Yoann Pradat, Maria Rosa Ghigna, Ghada Nachabeh, Alexia Alfaro, Cyril Catelain, Bastien Job, Fathia Mami-Chouaib, Severine Badel, Stephanie Corgnac, Françoise Farace, Marianne Oulhen, Patricia L. Kannouche, Nathalie Droin, Marie Wislez, Christos Chouaid, Hubert Curcio, Sophie Cousin Verified, Celine Mascaux, Jacques Cadranel, Margaux Geier, Rasha Cheikh-Hussin, Pierre Guyader, Nicholas Signolle, Karine Godefroy, Hugues Talbot, Maria Vakalopoulou, Stergios Christodoulidis, Elsa Bernard, Yves Akoli Koudou, Valerie Camara, Abdelhafidh Belarkemi, alexis klein, Jean Philippe Morretton, Philip East, Rachel Chiaverelli, Ricardo Zwirtes, Stefan Michiels, Fabrice Barlesi, Fabrice André, Guillaume Montagnac, Barbara Pistilli
| Cell Press Verified
Keywords ADC Dato-DXd mechanism of action response resistance NSCLC TROP2 internalization Introduction In 2022, lung cancer was the most frequently diagnosed cancer, with about 2.5 million new cases, and the leading cause of cancer death, with 1.8 million deaths worldwide.1 Several targeting therapies have been developed and approved over the past years for the treatment of metastatic lung cancer, particularly for non-small cell lung cancer (NSCLC); however, only 35%–40% of patients with...
Open in Who Shared Issue with article?

Full article: Clinical characteristics, healthcare resource use, and survival outcomes among patients with advanced NSCLC tested for KRAS mutations in France, the United Kingdom, and Switzerland

|
By Marie Wislez, Andromachi Giannopoulou, Isabelle Borget, Colin Lindsay
| Taylor & Francis Online
Abstract Objective To evaluate real-world patient characteristics, healthcare resource use (HRU), and clinical outcomes among patients with advanced or metastatic (A/M) non-small cell lung cancer (NSCLC) stratified by KRAS mutation status (KRAS G12C, KRAS non-G12C, and KRAS wild-type[WT]). Methods This retrospective chart review included adults with A/M NSCLC and known KRAS status who received second- or third-line non-targeted therapy (index therapy) in France, the UK, or Switzerland.
Open in Who Shared Issue with article?

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

|
By Yi-Long Wu, Valentina Guarneri, Marie Wislez, Hôpital Cochin
| The Lancet Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Chmielecki, J ∙ Gray, JE ∙ Cheng, Y ∙ et al. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer Nat Commun. 2023; 14, 1070 2. Choudhury, NJ ∙ Marra, A ∙ Sui, JSY ∙ et al. Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers J Thorac Oncol. 2023; 18:463-475 3.
Open in Who Shared Issue with article?
See all 6 licensed articles (8 Total)